Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / Insulet securities class action lawsuit
Regulatory securities class action

Insulet securities class action lawsuit

Analysis based on 7 articles · First reported Jul 08, 2026 · Last updated Jul 15, 2026

Sentiment
-40
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Insulet Corporation's stock dropped a cumulative 24% across the two corrective disclosures, erasing significant market value. The lawsuit and ongoing quality concerns may further pressure the stock and damage investor confidence in the company's manufacturing controls.

Medical Devices Healthcare
Event Summary

A securities class action lawsuit has been filed against Insulet Corporation Corporation (NASDAQ: PODD) by Levi & Korsinsky, LLP, alleging that the company made materially false or misleading statements regarding the safety of its Omnipod insulin delivery devices and the scope of manufacturing defects at its Acton, Massachusetts facility. The class period runs from February 21, 2025 to May 26, 2026. After two Medical Device Corrections (MDCs) in March and May 2026, Insulet Corporation's stock price fell from approximately $236 to $146.01 per share. The first MDC affected certain Omnipod 5 lots, while the second revealed that cannula tear defects extended across Omnipod 5, Omnipod Dash, and Omnipod Eros products, affecting approximately 7 million Pods (8.5% of 2025 global production). The lawsuit alleges that Insulet Corporation downplayed the scope of the defects between the two MDCs, claiming the issue was limited to specific lots, while the FDA later disclosed 476 Medical Device Reports potentially linked to the March MDC, far exceeding Insulet Corporation's initially reported 29 Serious Adverse Events. Goldman Sachs questioned whether Insulet Corporation's references to the March MDC sufficiently captured the magnitude of the quality issues. The lead plaintiff deadline is August 31, 2026.

Key Actions
90 Insulet Corporation disclosed manufacturing issue
70 Insulet Corporation downplayed scope of defect
60 Levi & Korsinsky filed securities class action Insulet Corporation
50 United States — Food and Drug Administration disclosed 476 Medical Device Reports Insulet Corporation
30 Goldman Sachs questioned Insulet Corporation's quality narrative Insulet Corporation
Entities Involved
stock
Insulet Corporation
Insulet Corporation is the defendant in the securities class action, facing allegations of misleading investors about manufacturing defects. The stock price declined sharply after two Medical Device Corrections, and the company's reputation and financial standing are at risk.
Importance 100.0 Sentiment -60.0
govactor
United States — Food and Drug Administration
The FDA disclosed 476 Medical Device Reports potentially linked to the March MDC, which exceeded Insulet Corporation's initial disclosure of 29 Serious Adverse Events. This information is central to the allegations of understated scope.
Importance 40.0 Sentiment 0.0
priv
Levi & Korsinsky
Levi & Korsinsky is the law firm representing the class action plaintiffs. The firm is seeking lead plaintiff appointment and potential recovery for investors.
Importance 30.0 Sentiment 0.0
stock
Goldman Sachs
Goldman Sachs questioned whether Insulet Corporation's references to the March MDC sufficiently captured the magnitude of the quality issues, adding to negative sentiment around the company.
Importance 20.0 Sentiment 0.0
per
Joseph E. Levi
Joseph E. Levi is a partner at Levi & Korsinsky and is quoted in the press releases regarding the lawsuit. He is acting as legal counsel for the plaintiffs.
Importance 20.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ Levi & Korsinsky
United States — Food and Drug Administration related ↔ Goldman Sachs
United States — Food and Drug Administration related ↔ Joseph E. Levi
Levi & Korsinsky related ↔ Joseph E. Levi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.